ORYZON Raises €12 Million and Signs a Financing Agreement with COFIDES to Strengthen its Balance Sheet and Accelerate its Clinical Programs
MADRID and CAMBRIDGE, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code:ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today announced the successful completion of a €12 million gross capital increase through the issuance o…